Immutep has announced a partnership with MSD to assess the effectiveness of Efti alongside KEYTRUDA in a crucial Phase III study.

Phase III collaboration will evaluate efti in combination with KEYTRUDA, MSD’s anti-PD-1 therapy, and standard chemotherapy in first-line non-small cell lung cancer (1L NSCLC)TACTI-004 Phase III…

Read More: https://www.globenewswire.com/news-release/2024/06/03/2891872/0/en/Immutep-Announces-Clinical-Collaboration-with-MSD-to-Evaluate-Efti-in-Combination-with-KEYTRUDA-pembrolizumab-in-Pivotal-Phase-III-Trial.html